Mitigating ADA matrix interferences: semiquantitative double immunoprecipitation for anti-bevacizumab antibody in plasma
- 17 December 2025
- journal article
- Published by Taylor & Francis in Bioanalysis
- Vol. 17 (24) , 1731-1745
Abstract
Hybrid LC - MS/MS methodology offers orthogonal ADA quantitation but is limited by endogenous immunoglobulin matrix interference challenges. We developed a novel semi-quantitative LC-MS/MS isotyping assay for rabbit IgG/IgM immunogenicity in K2EDTA plasma using double immunoprecipitation with double acid dissociation. As compared to single immunoprecipitation, double immunoprecipitation reduced endogenous IgG by ≥90% and IgM by >95% (W1B1) or >55% (W3B2), improved peak-area ratios, and achieved an LLOQ of 100 ng/mL, with acceptable accuracy and precision. Double immunoprecipitation plus acid dissociation mitigates matrix interference and enables robust semi-quantitative hybrid LC-MS/MS ADA isotyping in rabbit plasma.Keywords
Funding Information
- Pharmaceutical Product Development (PPD), a part of Thermo Fisher Scientific
This publication has 13 references indexed in Scilit:
- Selection of positive controls and their impact on anti-drug antibody assay performanceJournal of Immunological Methods, 2024
- Anti-drug Antibody Validation Testing and Reporting HarmonizationThe AAPS Journal, 2021
- Isotyping and Semi-Quantitation of Monkey Anti-Drug Antibodies by Immunocapture Liquid Chromatography-Mass SpectrometryThe AAPS Journal, 2021
- Detection of cynomolgus monkey anti-protein XYZ antibody using immunocapture-LC/MSJournal of Applied Bioanalysis, 2016
- Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical RelevanceJournal of Immunology Research, 2016
- Development of Immunocapture-LC/MS Assay for Simultaneous ADA Isotyping and SemiquantitationJournal of Immunology Research, 2016
- Recommendations for Validation of LC-MS/MS Bioanalytical Methods for Protein BiotherapeuticsThe AAPS Journal, 2014
- Innovative Use of LC-MS/MS for Simultaneous Quantitation of Neutralizing Antibody, Residual Drug, and Human Immunoglobulin G in Immunogenicity Assay DevelopmentAnalytical Chemistry, 2014
- Assessing Immunogenicity in the Presence of Excess Protein Therapeutic Using Immunoprecipitation and Quantitative Mass SpectrometryAnalytical Chemistry, 2008
- Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancerJournal of Clinical Pharmacy and Therapeutics, 2007